PCNA expression as a marker of proliferation in benign and highly differentiated malignant tumors of the human thyroid gland (literature review and clinical case)
Full Text:PDF (Українська)
Smith SJ, Gu L, Phipps EA, et al. A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer. Mol Pharmacol. 2015 Feb;87(2):263-76. doi: 10.1124/mol.114.093211.
Guda BB, Pushkarev VV, Zhuravel EV, et al. Expression of proliferative cells nuclear antigen (PCNA) in normal tissues and in benign, poorly differentiated malignant (with metastatic lesions and without metastases) human thyroid tumors. Reports of National Academy of Science of Ukraine. 2015;10:93-7. (In Ukrainian).
Guda BB, Pushkarev VM, Pushkarev VV, et al. The expression and activation of extracellular signal-regulated kinase-1/2 and proliferating cell nuclear antigen content in normal tissue and human thyroid tumors. SM J Endocrinol Metab. 2015;1(1):1002.
Tomás G, Tarabichi M, Gacquer D, et al. A general method to derive robust organ-specific gene expression-based differentiation indices: application to thyroid cancer diagnostic. Oncogene. 2012 Oct 11;31(41):4490-8. doi: 10.1038/onc.2011.626.
Liang HS, Zhong YH, Luo ZJ, et al. Comparative analysis of protein expression in differentiated thyroid tumours: a multicentre study. J Int Med Res. 2009 May-Jun;37(3):927-38. doi: 10.1177/147323000903700339.
Konturek A, Barczyński M, Nowak W, Richter P. Prognostic factors in differentiated thyroid cancer – a 20-year surgical outcome study. Langenbecks Arch Surg. 2012 Jun;397(5):809-15. doi: 10.1007/s00423-011-0899-z.
Chaudhary SC, Singh T, Talwelkar SS, et al. Erb-041, an estrogen receptor-b agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014 Feb;7(2):186-98. doi: 10.1158/1940-6207.CAPR-13-0276.
Polotskaia A, Xiao G, Reynoso K, et al. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1220-9. doi: 10.1073/pnas.1416318112.
Punchihewa C, Inoue A, Hishiki A, et al. Identification of small molecule proliferating cell nuclear antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication. J Biol Chem. 2012 Apr 20;287(17):14289-300. doi: 10.1074/jbc.M112.353201.
Li P, Wang Q, Wang H. MicroRNA-204 inhibits the proliferation, migration and invasion of human lung cancer cells by targeting PCNA-1 and inhibits tumor growth in vivo. Int J Mol Med. 2019 Mar;43(3):1149-1156. doi: 10.3892/ijmm.2018.4044.
Lu YC, Wang P, Wang J, Ma R, Lee SC. PCNA and JNK1-Stat3 pathways respectively promotes and inhibits diabetes-associated centrosome amplification by targeting at the ROCK1/14-3-3σ complex in human colon cancer HCT116 cells. J Cell Physiol. 2019 Jul;234(7):11511-11523. doi: 10.1002/jcp.27813.
Becker JR, Gallo D, Leung W, et al. Flap endonuclease overexpression drives genome instability and DNA damage hypersensitivity in a PCNA-dependent manner. Nucleic Acids Res. 2018 Jun 20;46(11):5634-5650. doi: 10.1093/nar/gky313.
Qiu X, Mei J, Yin J, Wang H, Wang J, Xie M. Correlation analysis between expression of PCNA, Ki-67 and COX-2 and X-ray features in mammography in breast cancer. Oncol Lett. 2017 Sep;14(3):2912-2918. doi: 10.3892/ol.2017.6516.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2020